台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

附件10 訓練醫院評鑑委員會(0331)

2021-04-27 • 觀看: 21 • 回應: 0 • pdf
附件09 基層醫療委員會0325

2021-04-27 • 觀看: 9 • 回應: 0 • pdf
附件08 泌腫委員會

2021-04-27 • 觀看: 21 • 回應: 0 • pdf
(IS6-2) Immuno-oncology combination therapies in first-line metastatic renal-cell carcinoma_蘇柏榮

2021-04-22 • 觀看: 11 • 回應: 0 • 影片
(IS5-2) Practical considerations in managing nocturia in male LUTS_許毓昭

2021-04-22 • 觀看: 10 • 回應: 0 • 影片
(LS5-1) Balversa in FGFR-altered advanced urothelial carcinoma_葉士芃

2021-04-22 • 觀看: 5 • 回應: 0 • 影片
(IS5-1) Impact of neoadjuvant Degarelix on section margin and biochemical outcomes after robotic assisted radical prostatectomy for advanced prostate cancer_林威宇

2021-04-22 • 觀看: 0 • 回應: 0 • 影片
(IS6-1) The efficacy of Immunotherapy in mRCC Real world experience in VGHTC_李建儀

2021-04-22 • 觀看: 10 • 回應: 0 • 影片
(IS2-2) Towards the evidence of perioperative immunotherapy in MIBC_魏子鈞

2021-04-22 • 觀看: 2 • 回應: 0 • 影片
(IS2-1) Future trends of immunotherapy management in urothelial carcinoma_薛富仁

2021-04-22 • 觀看: 5 • 回應: 0 • 影片
(IS1-2) Darolutamide Prioritizing overall survival without compromising quality of life in men with nmCRPC_王賢祥

2021-04-22 • 觀看: 12 • 回應: 0 • 影片
(IS1-1) Optimizing treatment in mCRPC patients with Radium-223_林柏宏

2021-04-22 • 觀看: 8 • 回應: 0 • 影片

Prev
486
487
488
489
490
491
492
493
494
495
Next
/ 1052